Myriad Genetics, Inc. ( MYGN) - Key Metrics
MYGN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $2.01 | -$0.46 | -$0.09 | -$0.11 |
| 2026Q1 | $2.14 | -$0.36 | -$0.17 | -$0.23 |
| 2025Q4 | $2.25 | -$0.08 | $0.11 | $0.05 |
| 2025Q3 | $2.21 | -$0.29 | $0.23 | $0.20 |
| 2025Q2 | $2.30 | -$3.57 | -$0.15 | -$0.22 |
MYGN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -3.10 |
| 2026Q1 | 0% | -3.13 |
| 2025Q4 | 0% | -18.15 |
| 2025Q3 | 0% | -6.23 |
| 2025Q2 | 0% | -0.37 |
MYGN
Price: $3.98
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.23 USD
Exchange: NMS
Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Volume: 315100
Ebitda: 17.5 millionMarket Capitalization: 428.8 million